Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its fourth
quarter 2013 financial results on Tuesday, March 11, 2014, after the
market closes. The earnings news release will be available on the Furiex
website at www.furiex.com.
On Wednesday, March 12, 2014, at 9 a.m. ET, Furiex will conduct a live
conference call and audio webcast to discuss financial results and
product portfolio. A Q&A session will follow. The conference call will
be broadcast live over the Internet and will also be available using the
following direct dial numbers:
Participant dial-in:
|
|
|
+1 877 677 9122 (U.S./Canada)
|
|
|
|
+1 708 290 1401 (International)
|
Conference ID:
|
|
|
11398508
|
All interested parties can access the webcast through the Presentations
& Events link in the Investors section of the Furiex website at www.furiex.com.
The webcast will be archived shortly after the call for on-demand replay.
About Furiex Pharmaceuticals
Furiex Pharmaceuticals is a drug development collaboration company that
uses innovative clinical development design to accelerate and increase
value of drug development programs by advancing them through the drug
discovery and development process in a cost-efficient manner. Our drug
development programs are designed and driven by a core team with
extensive drug development experience. The company collaborates with
pharmaceutical and biotechnology companies and has a diversified product
portfolio and pipeline with multiple therapeutic candidates, including
one Phase III-ready asset, two compounds in Phase III development, one
of which is with a partner, and four products on the market. The
company's mission is to develop innovative medicines faster and at a
lower cost, thereby improving profitability and accelerating time to
market while providing life-improving therapies for patients. For more
information, visit www.furiex.com.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140210006406r1&sid=ntxv4&distro=nx)
Copyright Business Wire 2014